Phase III DFP-10917 Trial Interim Update for R/R AML Patients

Delta-Fly Pharma, a pharmaceutical company based in Japan, has recently announced an update on their ongoing Phase III clinical trial for a drug candidate, DFP-10917. This trial is focused on treating patients with recurrent or refractory acute myeloid leukemia (R/R AML) across multiple centers in the United States.

The interim analysis of the study has revealed that there are patients who have been enrolled for an extended period, indicating a potential for long-term survival. As a result, the company has decided to continue monitoring these individuals without implementing a data cut-off at this stage. This decision is aimed at accurately determining the final overall survival (OS) outcomes of the study.

It is important to note that due to the randomized and controlled nature of the study, the company is currently unable to disclose whether these long-term surviving patients belong to the DFP-10917 treatment group or the control group. The trial is registered under the identifier NCT03926624.

Delta-Fly Pharma is dedicated to making a significant impact on the lives of cancer patients through innovative treatments. The company is eager to share the results of the study once the data is ready for public disclosure.

While the company's contact information and the source of the news release are not included in this summary, it is clear that Delta-Fly Pharma is committed to advancing cancer research and improving patient outcomes. The company's efforts in the development of DFP-10917 for R/R AML are a testament to their dedication to finding effective treatments for this challenging disease.